Entrada Therapeutics, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • October 8th, 2021 • Entrada Therapeutics, Inc. • Pharmaceutical preparations • New York
Entrada Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”), for whom you are acting as Representatives, an aggregate of [●] shares (the “Firm Shares”) and, at the election of the Underwriters, up to [●] additional shares (the “Optional Shares”) of common stock, par value $0.0001 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
EXCLUSIVE LICENSE AGREEMENT AGT. NO.________Exclusive License Agreement • October 8th, 2021 • Entrada Therapeutics, Inc. • Pharmaceutical preparations • Ohio
This Exclusive License Agreement (the “Agreement”) is made this 14th day of December, 2018 (the “Effective Date”) by and between the Ohio State Innovation Foundation, with an address at 1524 North High Street, Columbus, OH 43201 (hereinafter, “OSIF”) and Entrada Therapeutics, Inc., with an address at 16 Cavendish Court, Suite 401, Lebanon, NH 03766 (hereinafter, “Licensee”); collectively, “Parties”, or singly, “Party”.
License AgreementLicense Agreement • October 8th, 2021 • Entrada Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This License Agreement, made and entered into as of February 28, 2020 (“Agreement”), is by and between Entrada Therapeutics, Inc., a Delaware domestic corporation, having a place of business located at 50 Northern Avenue, Boston MA 02210 (“Licensee”) and MIL 6T, LLC a Delaware limited liability company having a place of business located at 6 Tide Street, Boston, MA 02110 (“Licensor”).
